Abbisko Therapeutics Co., Ltd. announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib in treating patients with advanced tenosynovial giant cell tumor, will be released at the 2023 American Society of Clinical Oncology annual meeting to be held in Chicago, USA from June 2 to June 6, 2023.
